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ㅋ
Advances in basic and clinical research have revealed that Helicobacter pylori ( H. pylori) infection plays an important role in 
the development of gastroduodenal dysmotility and hypersensitivity, as also in dyspepsia symptoms. In addition, recent studies 
have proposed an inflammation-immunological model for the pathogenesis of functional dyspepsia. Since H. pylori is the ma-
jor microbe that provokes a gastroduodenal inflammatory response, it should not be overlooked when considering the patho-
physiology of dyspepsia symptoms. In fact, population-based studies have demonstrated that H. pylori i s  d et ec t ed  mor e fr e-
quently in dyspepsia patients. However, although many clinical studies tried to reveal the association of H. pylori infection with 
gastric motility dysfunction or hypersensitivity, the results have been conflicting. On the other hand, many etiological features 
were revealed for the development of H. pylori-associated dyspepsia, such as abnormal ghrelin or leptic secretion, altered ex-
pression of muscle-specific microRNAs, and duodenal inflammatory cell infiltration. In addition, therapeutic strategy for H. py-
lori-associated dyspepsia would be different from H. pylori-negative functional dyspepsia. This review focuses the issue of 
whether  H. pylori-associated dyspepsia should be considered as a different disease entity from functional dyspepsia.
(J Neurogastroenterol Motil 2011;17:124-130)
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Introduction
Functional dyspepsia (FD) is a syndrome characterized by 
chronic and recurrent gastroduodenal symptoms in the absence 
of any organic or metabolic disease that is likely to explain the 
symptoms.
1,2 FD is considered to be important to public health, 
because it is remarkably common, can be disabling, and can pose 
a major social and economic burden.
3 Since FD is a highly heter-
ogeneous disorder, numerous pathophysiological mechanisms, 
such as gastroduodenal motor dysfunction, visceral hypersen-
sitivity, central nervous system dysfunction, Helicobacter pylori 
(H. pylori) infection and psychosocial factors have been suggested 
to play a role in the development of FD.
Although numerous epidemiological trials have suggested a 
higher prevalence of H. pylori infection in FD patients, the results 
have been conflicting.
4 Results of a meta-analysis showed that the 
prevalence of H. pylori infection was greater in patients with dys-H. pylori and Functional Dyspepsia
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p e p s i a  t h a n  i n  c o n t r o l s ,  w i t h  a n  o d d s  r a t i o  o f  2 . 3  ( 9 5 %  C I ,  
1.9-2.7).
5 Although this result seems to support the role of H. pylori 
infection in the pathogenesis of dyspepsia, it appears that some of 
the studies that were included in the analysis were biased by the 
selection of controls not properly matched for age, socioeconomic 
status and ethnic background.
4
However, recent studies have revealed a subset of patients 
who developed FD after an episode of gastrointestinal infection. 
These studies, proposing the concept of post-infectious FD, sug-
gest that an inflammation-immunological circuit also plays an im-
portant role in the development of FD.
6 It is generally well-rec-
ognized that the major cause of gastroduodenal inflammation is 
H. pylori infection.
7 Since H. pylori induces activation of a com-
plex and fascinating cytokine and chemokine network in the gas-
tric mucosa,
8 it is of little surprise that H. pylori infection has been 
implicated in the pathogenesis of dyspepsia. 
For this reason, one of the major research interest is the dif-
ference between H. pylori-associated dyspepsia and other func-
tional dyspepsia.
9 In this review article, FD in patients with a 
present or even past history of H. pylori infection is defined as a 
different disease entity (H. pylori-associated dyspepsia [HpD]) 
from FD, especially by focusing on the etiological insight of 
HpD, and then discusses the therapeutic strategy of HpD.
Influence of Helicobacter pylori Infection 
on Dyspepsia Symptoms and the Gastric 
Functions
A lot of clinical evidences have been published to investigate 
whether H. pylori infection is involved in gastric motility dis-
orders and visceral hypersensitivity. However, all of these studies 
were small-scale studies, and the results were conflicting. Few 
studies have shown the association between gastric visceral hyper-
sensitivity and H. pylori infection. Thumshirn et al
10 compared 
gastric motor and sensory functions in 17 patients with FD and 
16 asymptomatic controls, and reported that H. pylori infection 
did not appear to influence gastric accommodation, but was asso-
ciated with hypersensitivity in FD patients. On the other hand, 
some researchers were able to show the association between gas-
tric motility dysfunction and H. pylori infection. Mearin et al
11 in-
vestigated the symptomatic pattern in 27 H. pylori-positive and 
23 H. pylori- negative patients with FD, and showed that FD pa-
tients with H. pylori infection presented no distinctive symptoms 
in comparison with their H. pylori-negative counterparts, and that 
H. pylori infection was associated with diminished postprandial 
antral motility, but did not increase the perception of gastric 
distension. Tucci et al
12 evaluated the H. pylori infection status, 
histological features of the gastric mucosa, and the gastric motor 
and secretory functions in 45 consecutive patients with FD. H. 
pylori infection was found in 60% of FD patients, as compared 
with 33% of the 15 healthy controls. No difference was detected 
in the basal or stimulated gastric acid secretion between the FD 
patients and healthy controls. Gastric emptying was significantly 
delayed in FD patients as compared with that in healthy controls 
after adjustments for age and sex. Delayed gastric emptying was 
associated with a low frequency of H. pylori infection, female gen-
der and young age. Epigastric pain or burning and postprandial 
fullness were more severe in patients with H. pylori infection and 
in those with delayed gastric emptying, respectively. Saslow et al
13 
compared 8 H. pylori- positive and 8 H. pylori-negative asympto-
matic subjects, and showed that H. pylori infection reduced ac-
commodation, but had no effect on the overall sensation or motor 
functions of the stomach. However, some studies showed that H. 
pylori infection did not affect gastric motility or hypersensitivity. 
Leontiadis et al
14 evaluated 23 FD patients and 17 controls, and 
showed that although gastric emptying was delayed in FD pa-
tients, the gastric emptying rate was not associated with the H. py-
lori infection status, and was also not affected by eradication of the 
infection. Chang et al
15 compared 22 H. pylori- negative patients 
and 38 H. pylori- positive patients with FD, and showed that the 
H. pylori infection status appeared to have no influence on the in-
cidence of delayed gastric emptying of digestible and indigestible 
solids. 
Although the results of several clinical studies suggest that 
H. pylori infection may play a role in the development of FD, the 
precise pathogenesis of HpD could not be elucidated. Since gas-
tric dysmotility and visceral hypersensitivity are induced by a 
number of confounding factors, such as diet, smoking and psy-
chosocial stress, the association of H. pylori infection with gastric 
sensation or motor dysfunction might be difficult to be revealed 
only by clinical studies. A large-scale clinical study controlled for 
all of these factors would be difficult to design. Thus, novel bio-
logical markers for HpD other than gastric dysmotility and hy-
persensitivity must be identified. On next section, therefore, the 
possible pathophysiology of HpD will be reviewed.
Pathophysiological Link Between Helicobacter 
pylori Infection and Dyspepsia
Traditionally, gastric acid hypersecretion induced by H. pylori Hidekazu Suzuki, et al
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infection of the gastric antral mucosa has been considered to play 
a role in the development of dyspepsia. About 10%-15% of pa-
tients with H. pylori infection show antral-predominant gastritis, 
which results in gastric acid hypersecretion.
16 In these patients, 
H. pylori induced a decrease in somatostatin secretion in the antral 
gland area, leading to an increase in the release of gastrin and 
subsequently to a rise in acid secretion.
17 This mechanism is also 
considered to underlie the development of duodenal ulcer. These 
phenomena are reversible, since normal feedback control of gas-
trin secretion is restored after H. pylori eradication.
17,18
However, a few studies investigating the association between 
the severity of histological gastritis and that of dyspepsia symp-
toms yielded different results. Turkkan et al
19 reported that dys-
pepsia symptom scores were higher in patients with mild or mod-
erate chronic inflammation of the corpus and antrum than in 
those with severe chronic inflammation, although the difference 
did not reach statistical significance. In studies conducted by 
Joshi et al
20 and Pereira-Lima et al,
21 no relationship was found 
between the severity of histological gastritis and the severity of the 
dyspeptic symptoms. Czinn et al
22 found a relationship between 
epigastric pain and the severity of inflammation. Similarly, van 
der Schaar et al
23 also found an indirect relationship between the 
severity of symptoms and the severity of inflammation of the 
corpus. From these results, we could not reach any definitive con-
clusion about the association of  severity of gastritis or amount of 
gastric acid secretion with severity of the dyspepsia symptoms. 
Ghrelin, which is produced and secreted by the A-like cells of 
the oxyntic glands of the stomach, has a well-established role in 
increasing appetite and food intake and in stimulating gastric 
emptying and acid secretion.
24-28 These functions are mediated, at 
least in part, via vagal nerve pathways.
29,30 In gastroduodenal mu-
cosal injury, the levels of plasma ghrelin increased in response to 
the physiological demand for the purpose of gastroduodenal cyto-
protection.
31,32 However, in the presence of H. pylori-induced se-
vere gastric mucosal atrophy, the plasma ghrelin concentrations 
shifted to lower levels.
33-36 Taken together, H. pylori infection 
may induce gastric motor dysfunction and reduce appetite with 
suppressed ghrelin secretion. Therefore, this peptide may play a 
role in the onset of FD, especially HpD. In fact, alterations of the 
plasma ghrelin levels have been reported in FD patients, which 
frequently correlated with the FD symptom score.
37-39 Some 
studies showed that plasma ghrelin levels were significantly lower 
in patients with dysmotility-like FD.
28,37 Concerning the active 
ghrelin levels, they were also decreased in patients with post-
prandial fullness and/or early satiation,
40 whereas similar between 
dysmotility-like FD patients and healthy controls.
37 Moreover, 
recent study showed that repeated ghrelin administrations had 
stimulatory effects on food intake in FD patients.
41 However, the 
opposite results, such as enhanced ghrelin levels in FD patients, 
were also reported.
38,42 Leptin is also produced in the stomach, 
and activates vagal nerve ternimals, reduces appetite and in-
creases mucin secretion.
43 Leptin may also play a role in the onset 
of FD, since patients with dysmotility-like dyspepsia have been 
reported to show higher serum concentrations of leptin.
44 On the 
other hand, serum leptin levels and expression of leptin mRNA 
in the gastric mucosa was enhanced in H. pylori-positive pa-
tients,
44,45 suggesting that H. pylori infection may reduce appatite 
with enhanced leptin secretion. The circulatory levels of ghrelin 
and leptin in HpD patients have not yet been investigated, war-
ranting future research. 
We recently investigated the role of microRNAs (miRNAs) 
in gastric motility disorders associated with H. pylori infection,
46 
and the results provided a novel insight into the molecular patho-
genesis of HpD. Histologic examination showed prominent thic-
kening of the muscular layer of the gastric corpus in H. pylori-in-
fected mice. In addition, gastric emptying was significantly accel-
erated in H. pylori-infected mice. The miRNA expression profile 
revealed that the muscle-specific miRNAs, miR-1, miR-133a and 
miR-133b, were downregulated in the stomach of H. pylori- in-
fected mice. The expression levels of histone deacetylase 4 and se-
rum response factor, which are target genes of miR-1 and miR- 
133 known to enhance muscular hyperproliferation, were in-
creased. Taken together, chronic H. pylori infection down-
regulates the expressions of muscle-specific miRNAs and upre-
gulates the expression of histone deacetylase 4 and serum re-
sponse factor, which might cause hyperplasia of the muscular lay-
er of the stomach and deregulation of gastric emptying in mice. 
Further human studies will be necessary to validate the associa-
tion between aberrant expression of muscle-specific miRNAs in 
the muscular layer of the stomach and HpD.
Duodenum - A Crossroad Between Helicobacter 
pylori and Dyspepsia
Recent studies have emerged implicating abnormal motor 
and autonomic responses in the duodenum perhaps triggering 
functional responses, including pain and abnormal gastric 
emptying. Increased duodenal acid exposure has been reported in 
patients with dyspepsia symptoms. At the level of the duodenum, 
abnormalities may exist in the stimulus intensity, mucosal H. pylori and Functional Dyspepsia
       
127 Vol. 17, No. 2 April, 2011 (124-130)
mRNA expression, biosynthesis, release or inactivation of the 
mucosal mediators, or in the receptor expression on the afferent 
nerve endings.
47
Furthermore, Talley et al
48 proposed that changes in the duo-
denal eosinophil count might be an underlying feature of FD. 
They also showed that eosinophils were significantly increased in 
both the bulb and second portion of the duodenum in FD, 
whereas increase of the mast cells in the second portion of the du-
odenum was noted in irritable bowel syndrome (IBS).
49,50 A link 
between eosinophils (and other inflammatory cells) and FD 
would have therapeutic implications. Eosinophils are critically 
dependent on the cytokine IL-5 for their maturation in the bone 
marrow, which also influences eosinophil migration and survival. 
Kindt et al
51 reported that stimulated lymphocyte expression of 
IL-5 and IL-13 was enhanced, whereas stimulated monocytic 
IL-12 and lymphocytic IL-10 expression were reduced in both 
FD and IBS. Based on these findings, anti-inflammatory agents, 
possibly including novel biologics such as anti-IL-5 humanized 
antibodies, could be explored as a possible therapeutic candidates 
for FD.
Active duodenitis has been reported to be more common in 
patients with H. pylori infection.
52 Genta et al
52 reported that H. 
pylori was detected in the gastric metaplastic epithelium of 67.6% 
of patients with active inflammation of the duodenum. On the 
other hand, H. pylori infection is well-known to cause eosinophil 
infiltration of the gastric mucosa.
53 Taken together, H. pylori 
might be one of the causes of duodenal eosinophilia, as well as of 
the onset of dyspepsia symptoms.
In addition, Gargala et al
54 reported that the number of intra-
epithelial lymphocytes in the duodenal mucosa was significantly 
greater in H. pylori-positive FD patients than in healthy controls, 
but not different between H. pylori-negative FD patients and 
healthy controls. The expressions of CD95/Fas and HLA-DR- 
expressing CD3
+ lymphocytes were lower in H. pylori-negative 
FD patients than in healthy controls. These findings suggest that 
the phenotypic characteristics of intraepithelial lymphocytes may 
be different between HpD and H. pylori-negative FD.
Treatment for Helicobacter pylori-Associated 
Dyspepsia
Although a number of clinical trials have assessed the efficacy 
of H. pylori eradication for the treatment of FD, the studies drew 
different conclusions. However, it is quite clear that H. pylori 
eradication treatment is effective in at least a subset of patients 
with FD.
7,55-58 According to a meta-analysis of randomized con-
trolled trials to determine the effect of H. pylori eradication on 
dyspepsia symptoms, H. pylori eradication therapy appears to 
have a small but statistically significant effect in HpD.
59 Harvey 
et al
60 showed that H. pylori eradication gave cumulative long- 
term benefit, with a continued reduction in the development of 
dyspepsia severe enough to require a consultation with a general 
practitioner up to at least 7 years.
The efficacy for patients with HpD in Asia would be differ-
ent from those in Western countries, since Asian population dif-
fers from the Western population in many respects, such as prev-
alent H. pylori strains, including cagA gene polymorphisms, lev-
els of acid secretion in the stomach and the severity or pattern of 
gastritis.
58,61 In fact, Gwee et al
62 showed that the patients with 
FD in Asia would have a benefit from treatment for H. pylori in-
fection with as much as a 13-fold increased chance of symptom 
resolution following its eradication in a double blind, randomized 
and placebo-controlled trial in Singapore-based Asian population.
There is no evidence of treatment for HpD patients after the 
successful eradication of H. pylori. At present, acid suppression is 
a frequently used first-line therapy for FD. A meta-analysis of 
randomized controlled trials of proton pump inhibitors (PPIs) 
for FD reported that this class of agents was superior to pla-
cebo.
63 However, much of this benefit may be explained by the 
presence of concomitant unrecognized gastroesophageal reflux 
disease (GERD). Xiao et al
64 showed that the prevalence of 
pathologic esophageal acid reflux without typical reflux symp-
toms (silent reflux) was 31.7% in FD patients. In addition, PPIs 
were effective in 83.1% of FD patients with silent reflux, and in 
54.3% of those without silent reflux. On the other hand, inverse 
associations are observed between the presence of H. pylori in-
fection and GERD, because of the reduction in gastric acid pro-
duction by H. pylori colonization of the gastric mucosa.
65,66 This 
suggests that the efficacy of PPIs in HpD may be weaker than 
that in H. pylori-negative FD, which may show strong overlap 
with GERD. 
On the other hand, a gastro-protective agent for chronic gas-
tritis would be a therapeutic candidate for HpD. Rebamipide, a 
gastro-protective anti-ulcer drug, has been used for the improve-
ment of dyspepsia symptoms in Japan, Korea, China and some 
other countries. Rebamipide is known to suppress gastric mu-
cosal inflammation, which is thought to be related to its activity in 
the inhibition of superoxide anion production from neutrophils 
and scavenging hydroxyl radicals.
67,68 Rebamipide administration 
after H. pylori eradication could promote the restoration of atroHidekazu Suzuki, et al
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phic mucosa in Mongolian gerbils.
69 Chitapanarux et al
70 re-
ported that rebamipide treatment improved symptom, endo-
scopic and histologic features of chronic gastritis in patients with 
dyspepsia symptoms refractory to PPIs. Talley et al
71 reported a 
double-blind, placebo-controlled and multicenter study of re-
bamipide for the treatment of FD patients with or without H. 
pylori infection. Although a significant improvement of in-
dividual symptoms at 8 weeks was not detected, the ratio of pa-
tients who requested usage of the study medication again was 
greater in the rebamipide groups compared with the placebo 
group in H. pylori-positive patients. During the planning of this 
study, it was originally projected that a sample size of 100 patients 
per treatment group would be sufficient to detect a difference in 
response rate of approximately 20% between the rebamipide 
treatment group and the placebo treatment group with 80% pow-
er at the 0.05 significance level. However, because of the slow pa-
tient recruitment and unexpected budget constraints, the trial had 
stopped prior to completion of enrollment. Based on the enrolled 
population of approximately 50 patients per arm in the H. pylori- 
negative study and 30 patients per arm in the H. pylori-positive 
study, the detectable differences would be 30% and 40%, 
respectively. The 30% superiority over the placebo would be 
non-realistic hurdle for any medication for FD. Miwa et al
72 also 
reported a double-blind, placebo-controlled and single-center 
study of rebamipide for the treatment of FD patients. Although 
the mean changes in overall symptoms after 4 weeks of treatment 
were not significantly different between the rebamipide and pla-
cebo treatment groups, the improvement in symptom score was 
significantly greater in the rebamipide group for bloating, belch-
ing and pain or discomfort that was relieved after a meal. Social 
restriction and pain intensity were also improved in the re-
bamipide group. The ratio of subjects with H. pylori infection 
were 54.1% in the rebamipide group and 42.4% in the placebo 
group. However, they did not perform subanalysis by H. pylori 
status as the number of subjects was rather small. As rebamipide 
has an anti-inflammatory effect, it might be effective for HpD, 
but not for FD patients without gastritis. However, there is not 
enough evidence for the efficacy of rebamipide for dyspepsia 
symptoms of HpD patients.
Therefore, the efficacy of all the existing medical treatment, 
including a gastro-protective agent, for FD should be re-eval-
uated for HpD and H. pylori-negative FD. Well-designed studies 
to investigate a suitable therapeutic strategy for HpD are needed.
Conclusions
Several mechanisms have been postulated for the develop-
ment of HpD. Some of these mechanisms would be reversible, 
while others might not. Therefore, it would be reasonable that the 
H. pylori “test-and-treat” strategy is not effective in all HpD pa-
tients, but is effective in only a subset of HpD patients. H. pylori 
infection evokes significant inflammatory changes, not only in the 
gastric mucosa, but also in the gastric muscular layer as well as in 
the duodenum. However, most patients with H. pylori infection 
do not have any symptoms. We therefore need to conduct further 
investigation about the true relationship between dyspepsia 
symptoms and H. pylori infection to determine whether there 
might be identifiable risk factors for the onset of symptoms. 
When the Rome III criteria were developed, the role of H. 
pylori infection in FD was controversial. Now, however, the path-
ophysiology underlying disturbances of gastroduodenal motor or 
sensory function and dyspepsia symptoms caused by H. pylori in-
fection is gradually being elucidated. Therefore, when HpD is 
considered as an organic disease and as a different disease entity 
from FD, these conflicting results of previous studies might be-
come more comprehensible. Further studies will be necessary to 
determine whether HpD should be separated from FD. In addi-
tion, the differences in the therapeutic strategies between HpD 
and H. pylori-negative FD are also necessary to be investigated in 
the future.
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